Navin Kapur, MD
Cardiovascular Disease · Baltimore, MDNPI 1902959554
Payments from drug & device makers
Across 517 payments — averaging $3417.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1.4M
- Boston Scientific$154K
- Abbott$112K
- Livanova USA, Inc.$24K
- My01 Inc.$21K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$12K
- plus $19K from 21 others
Across 27 payments — averaging $5463.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$147K
- ZOLL Circulation Inc$220
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 358 | $1,424,237 |
| Boston Scientific | 9 | $153,585 |
| Abbott | 28 | $112,485 |
| Livanova USA, Inc. | 16 | $23,783 |
| My01 Inc. | 1 | $21,450 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $12,133 |
| Edwards Lifesciences | 5 | $5,568 |
| ZOLL Circulation Inc | 6 | $5,153 |
| Getinge USA Sales, LLC | 3 | $3,113 |
| Medtronic(2 entities) | 3 | $2,141 |
| Ancora Heart, Inc. | 5 | $1,400 |
| Johnson & Johnson | 17 | $469 |
| Amgen | 12 | $251 |
| Pfizer | 7 | $175 |
| Novartis | 10 | $154 |
| Teleflex LLC | 1 | $110 |
| Novo Nordisk | 5 | $103 |
| AstraZeneca | 5 | $99 |
| Shockwave Medical, Inc | 3 | $90 |
| Boehringer Ingelheim | 3 | $81 |
| Portola Pharmaceuticals, LLC | 2 | $37 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Cardiva Medical, Inc. | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
How this compares
$1,766,721 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Baltimore
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Robert WeissBaltimore$1.4M
- Stephen GottliebBaltimore$1.4M
- Jesse DoranBaltimore$1.1M
- Armin Arbab-ZadehBaltimore$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.